T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
CONMED
CNMD
$1.49B
| $21.8M | ﹤0.01% |
272,463
+1,915
| +0.7% | +$181K |
|
877
Sana Biotechnology
SANA
$1.1B
| $21.8M | ﹤0.01% |
3,640,503
+748,922
| +26% | +$5.4M |
|
|
CCC
878
CCC Intelligent Solutions
CCC
$4.19B
| $21.5M | ﹤0.01% |
2,362,039
-27,725,864
| -92% | -$262M |
|
879
iShares Core MSCI EAFE ETF
IEFA
$196B
| $21.5M | ﹤0.01% |
407,334
+215,899
| +113% | +$12.7M |
|
880
Bankunited
BKU
$3.41B
| $21.4M | ﹤0.01% |
625,956
-7,425,966
| -92% | -$278M |
|
881
Freshworks
FRSH
$3.51B
| $21.2M | ﹤0.01% |
1,636,879
+292,969
| +22% | +$4.14M |
|
882
Allegiant Air
ALGT
$2.36B
| $21M | ﹤0.01% |
288,415
-1,042,253
| -78% | -$108M |
|
883
Celldex Therapeutics
CLDX
$3.35B
| $21M | ﹤0.01% |
746,008
+212,606
| +40% | +$6.52M |
|
884
Pacira BioSciences
PCRX
$924M
| $20.9M | ﹤0.01% |
393,074
+4,384
| +1% | +$244K |
|
885
BellRing Brands
BRBR
$1.28B
| $20.9M | ﹤0.01% |
1,013,083
-5,671,128
| -85% | -$136M |
|
886
West Fraser Timber
WFG
$5.45B
| $20.7M | ﹤0.01% |
285,632
-1,268,255
| -82% | -$110M |
|
887
Sun Life Financial
SLF
$44.8B
| $20.7M | ﹤0.01% |
519,681
-15,502,156
| -97% | -$695M |
|
|
MRO
888
DELISTED
Marathon Oil Corporation
MRO
| $20.6M | ﹤0.01% |
912,969
-29,481
| -3% | -$699K |
|
889
Xylem
XYL
$28.1B
| $20.5M | ﹤0.01% |
235,170
+3,662
| +2% | +$333K |
|
890
Flywire
FLYW
$2.22B
| $20.5M | ﹤0.01% |
894,322
+91,582
| +11% | +$2.18M |
|
891
Graco
GGG
$13.3B
| $20.5M | ﹤0.01% |
342,320
-2,162,737
| -86% | -$139M |
|
892
Agilon Health
AGL
$1.49B
| $20.4M | ﹤0.01% |
34,916
-94,009
| -73% | -$56.3M |
|
|
SWCH
893
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $20.4M | ﹤0.01% |
605,929
+12,875
| +2% | +$436K |
|
894
Hewlett Packard
HPE
$79.2B
| $20.4M | ﹤0.01% |
1,703,858
-11,164
| -0.7% | -$152K |
|
|
PDCE
895
DELISTED
PDC Energy, Inc.
PDCE
| $20.2M | ﹤0.01% |
349,797
-60,025
| -15% | -$3.68M |
|
896
Range Resources
RRC
$9.33B
| $20.2M | ﹤0.01% |
799,200
-175,586
| -18% | -$5.31M |
|
|
AQUA
897
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
| $20.2M | ﹤0.01% |
610,346
+61,517
| +11% | +$2.23M |
|
898
Alpha Metallurgical Resources
AMR
$1.97B
| $20.1M | ﹤0.01% |
147,129
+2,168
| +1% | +$301K |
|
899
US Physical Therapy
USPH
$1.24B
| $20.1M | ﹤0.01% |
264,256
-979,641
| -79% | -$94.2M |
|
900
Natera
NTRA
$44.8B
| $20M | ﹤0.01% |
457,402
+406,276
| +795% | +$19.3M |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.